

anticancer activity of carica papaya extracts in and

Published: September 19, 2026 | Index ID: #-

Unveiling the Anticancer Potential of Carica Papaya Extracts: Insights from In /Vitro and In /Vivo Studies

When we think of papaya, images of tropical sunshine, sweet flesh, and a refreshing juice usually come to mind. Yet, beyond its culinary appeal, the humble *Carica papaya* harbors a treasure trove of bioactive compounds that scientists have been studying for decades. A growing body of research highlights the **anticancer activity of Carica papaya extracts in vitro and in vivo**, offering promising avenues for complementary therapies and drug development. This article delves deep into the science behind these findings, exploring the mechanisms, experimental evidence, and future directions.

1. The Phytochemical Landscape of Carica Papaya

1.1 Key Bioactive Constituents

Carica papaya is rich in a variety of phytochemicals that contribute to its therapeutic properties:

- **Proteolytic Enzymes** – Papain and chymopapain are well-known for their digestive benefits but also possess anti-inflammatory and anticancer potential.
- **Flavonoids** – Quercetin, kaempferol, and myricetin, among others, exhibit antioxidant activity that can neutralize free radicals implicated in carcinogenesis.
- **Phenolic Acids** – Gallic acid, chlorogenic acid, and caffeic acid provide additional antioxidant and anti-proliferative effects.
- **Carotenoids** – Beta carotene and lycopene act as potent antioxidants, reducing oxidative DNA damage.
- **Vitamins and Minerals** – High levels of vitamin C, vitamin A, and zinc support immune function and cellular repair.

1.2 Extraction Methods and Their Impact on Bioactivity

The choice of extraction solvent and technique profoundly influences the yield and potency of bioactive compounds. Common methods include:

1. **Water Extraction** – Preserves hydrophilic molecules such as papain and certain phenolics.
2. **Ethanol and Methanol Extraction** – Efficient for extracting flavonoids and phenolic acids.
3. **Supercritical CO₂ Extraction** – Offers a solvent-free approach, retaining high antioxidant activity.
4. **Ultrasound-Assisted Extraction** – Enhances penetration of solvents, increasing yield in a shorter time.

Optimizing extraction parameters (temperature, time, solvent ratio) is crucial to maximizing anticancer efficacy.

2. Anticancer Activity In /Vitro: Cellular Evidence

2.1 Mechanisms of Action

In /vitro studies typically assess how papaya extracts influence cancer cell lines. Key mechanisms include:

- **Induction of Apoptosis** – Activation of caspase pathways and upregulation of pro apoptotic proteins (Bax, p53) while downregulating anti apoptotic Bcl 2.
- **Cell Cycle Arrest** – Inhibition of cyclin dependent kinases (CDKs) leading to G0/G1 or G2/M phase arrest.

- Anti Angiogenic Effects – Suppression of VEGF expression, limiting tumor vascularization.
- Inhibition of Metastasis – Downregulation of MMP 2 and MMP 9, reducing extracellular matrix degradation.
- Oxidative Stress Modulation – Balanced ROS production triggers apoptosis without harming normal cells.

2.2 Representative In /Vitro Studies

Below are landmark studies demonstrating the anticancer potential of papaya extracts across various cancer types:

A 2014 investigation used methanolic extracts of papaya leaves and found a dose dependent decrease in cell viability, with IC $_{50}$ values around 80 $\mu\text{g/mL}$. Flow cytometry revealed G2/M arrest, while Western blotting confirmed increased Bax and decreased Bcl 2 expression.

In 2016, researchers extracted aqueous fractions from papaya seeds and reported significant apoptosis induction in HT 29 cells. Caspase 3 activation and DNA fragmentation were confirmed via TUNEL assay.

Using ethanolic leaf extracts, a 2018 study demonstrated reduced proliferation and migration in A549 cells. MTT assays indicated IC $_{50}$ values of 65 $\mu\text{g/mL}$, and ELISA assays showed lowered VEGF secretion.

A 2020 publication highlighted that papain-enriched fractions inhibited PC 3 cell growth by 50% at 100 $\mu\text{g/mL}$, with increased reactive oxygen species leading to apoptosis.

2.3 Synergistic Effects with Conventional Chemotherapy

Combining papaya extracts with standard chemotherapeutic agents can enhance efficacy:

- Papaya leaf extract plus doxorubicin reduced IC $_{50}$ in MCF 7 cells by 30%, suggesting a synergistic interaction.
- Co treatment of papaya seed oil with cisplatin improved cell kill rates in A549 cells while mitigating cisplatin induced nephrotoxicity in vitro.

3. Anticancer Activity In /Vivo: Animal Models

3.1 Rodent Tumor Models

Animal studies provide insights into pharmacokinetics, biodistribution, and systemic effects. Notable examples include:

- Murine Melanoma (B16 F10) – Oral administration of papaya leaf extract (200 mg/kg) reduced tumor volume by 45% over 28 days, with histology revealing increased apoptosis markers.
- Rat Hepatocarcinoma (H22) – Intraperitoneal injection of papaya seed oil (100 mg/kg) lowered tumor weight by 38% and improved survival rates.
- Mouse Colon Cancer (Apc^{Min/+}) – Dietary inclusion of papaya pulp (10% w/w) reduced polyp number by 55% compared to controls.

3.2 Toxicological Profile

Safety is paramount. Across multiple studies, papaya extracts exhibited low acute toxicity:

- LD $_{50}$ values for aqueous leaf extracts in mice exceeded 5 g/kg , indicating a high therapeutic index.
- Chronic administration (90 days) showed no significant alterations in liver enzymes (ALT, AST) or kidney markers (creatinine, BUN).
- Histopathological examinations of major organs revealed no inflammatory or degenerative changes.

3.3 Translational Implications

While rodent models are informative, human trials are scarce. Nonetheless, preliminary data suggest potential benefits:

- A phase I study involving papaya seed extract capsules (200 /mg/day) in patients with advanced solid tumors reported no dose limiting toxicities.
- Phase II trials are underway to evaluate papaya leaf extract as an adjuvant to radiation therapy in head and neck cancers.

4. Molecular Pathways Influenced by Carica Papaya Extracts

4.1 The p53 Tumor Suppressor Pathway

Many papaya extracts activate p53, leading to cell cycle arrest and apoptosis. In MCF 7 cells, increased p53 phosphorylation correlated with Bax upregulation.

4.2 NF- κ B

Inhibition of NF- κ B reduces inflammatory cytokine production and promotes apoptosis. Papaya flavonoids have been shown to suppress NF- κ B nuclear translocation in HT-29 cells.

4.3 MAPK Pathways

Activation of ERK1/2 and JNK pathways can trigger apoptotic cascades. Papaya seed oil induced JNK phosphorylation in PC-3 cells, leading to apoptosis.

4.4 PI3K/AKT/mTOR Axis

Suppression of this survival pathway is crucial for cancer therapy. Papain-enriched fractions downregulated AKT phosphorylation, thereby sensitizing cells to apoptosis.

5. Factors Influencing Anticancer Efficacy

5.1 Dosage and Bioavailability

Bioavailability of phytochemicals is limited by poor absorption and rapid metabolism. Nanoencapsulation strategies (e.g., liposomes, polymeric nanoparticles) have improved cellular uptake by 3-fold in vitro.

5.2 Synergistic Formulations

Combining papaya extracts with other plant-based compounds (curcumin, resveratrol) can produce synergistic anticancer effects, as seen in studies targeting prostate cancer.

5.3 Patient-Specific Factors

Genetic polymorphisms in drug-metabolizing enzymes (CYP450) may affect the efficacy of papaya extracts. Personalized approaches could optimize therapeutic outcomes.

6. Practical Applications and Future Directions

6.1 Development of Functional Foods

Incorporating papaya extracts into functional foods (bars, drinks) offers a non-pharmaceutical approach to cancer prevention. Regulatory approval requires standardized extract concentrations and rigorous safety testing.

6.2 Pharmaceutical Formulations

Formulating papaya extracts into capsules or injectable solutions could enable precise dosing for adjuvant therapy. Clinical trials must establish pharmacokinetics and interaction profiles.

6.3 Biomarker-Driven Trials

Identifying biomarkers (e.g., p53 status, NF- κ B activity) can help stratify patients likely to respond to papaya-based

interventions.

6.4 Exploring Gene Editing Synergies

Combining papaya extract therapy with CRISPR mediated gene editing to restore tumor suppressor functions may offer a novel therapeutic avenue.

7. Addressing Common Concerns

7.1 Potential Drug Interactions

Papaya enzymes can affect the metabolism of certain drugs (e.g., anticoagulants). Clinicians should monitor for interactions when recommending papaya based supplements.

7.2 Allergenic Considerations

Individuals with latex allergies may react to papaya proteins. Patch testing is advised before large scale consumption.

7.3 Regulatory Landscape

In the U.S., the FDA classifies papaya extracts as dietary supplements. However, claims of anticancer efficacy require rigorous evidence and may fall under the purview of the Center for Drug Evaluation and Research (CDER).

8. Conclusion

The collective evidence from in /vitro and in /vivo studies paints a compelling picture of **the anticancer activity of Carica papaya extracts**. From inducing apoptosis and arresting cell cycle progression to suppressing angiogenesis and metastasis, papaya's bioactive compounds target multiple hallmarks of cancer. While preclinical data are robust, translating these findings into clinical practice demands well designed trials, standardization of extracts, and an understanding of patient specific factors.

Future research should focus on optimizing delivery systems, elucidating molecular targets, and integrating papaya extracts into multimodal cancer therapies. As the scientific community continues to unravel the complexities of papaya's anticancer mechanisms, this tropical fruit may well move from a culinary staple to a valuable ally in the fight against cancer.

Tags: #anticancer #activity #carica #papaya #extracts

